By Megan Brooks
Source Medscape
Vitamin D supplementation significantly reduced the risk of relapse or death in a subgroup of patients with digestive tract cancer who were p53-immunoreactive, a recent analysis found.
In the p53-immunoreactive subgroup, daily vitamin D supplementation reduced the risk of relapse or death by 73%. Overall, the 5-year relapse-free survival (RFS) among those receiving vitamin D was 81% vs nearly 31% in the placebo group.
Vitamin D supplementation, however, had no effect on survival outcomes in the non-p53-immunoreactive subgroup.
Read more https://www.medscape.com/viewarticle/995848